What VOQUEZNA data will Phathom (PHAT) share at DDW 2026?

Phathom will present clinical, patient-reported, and real-world evidence across three poster presentations . According to Phathom, abstracts and poster details will be posted on the company's publications and scientific webpage after DDW concludes.

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

Q: When will Phathom Pharmaceuticals (PHAT) present VOQUEZNA at DDW 2026?

Phathom will present VOQUEZNA in a product theater on May 4, 2026 at 12:00 PM CDT . According to Phathom, the company will also display posters and exhibit at booth 2511 during DDW May 2–5 in Chicago.

Q: Where can investors find Phathom (PHAT) DDW 2026 abstracts and posters?

Posters and abstracts will be available on Phathom's publications page at www.phathompharma.com/publications/ after DDW. According to Phathom, the materials will be posted following the conference's conclusion for public access.

Q: Does the DDW 2026 presentation affect VOQUEZNA's approved uses for patients?

The DDW presentations report data; they do not change approved indications. According to Phathom, VOQUEZNA remains indicated for erosive and non-erosive GERD and H. pylori regimens as described in current prescribing information.

Q: How can healthcare professionals engage with Phathom (PHAT) about VOQUEZNA at DDW 2026?

Healthcare professionals can attend the May 4 product theater, visit booth 2511 , and review poster sessions. According to Phathom, company representatives and scientific staff will be available for discussion and follow-up during DDW.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Phathom Pharmaceuticals (Nasdaq: PHAT) will present VOQUEZNA® (vonoprazan) clinical and real-world data at Digestive Disease Week® (DDW) 2026 in Chicago, May 2–5. A product theater on VOQUEZNA is scheduled for May 4 at 12:00 PM CDT, and the company will exhibit at booth 2511.

Three poster presentations and post-meeting abstracts will be available on the company publications page.

News Market Reaction – PHAT

+7.23%

15 alerts

+7.23% Session close to close

+3.2% Peak Tracked

-4.8% Trough Tracked

$964.68M Market Cap

0.2x Rel. Volume

In the May 1 session, PHAT gained 7.23%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.2% during that session. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.2% in the session following this news. A strong positive reaction aligns with Pha...

Analysis

The stock moved +7.2% in the session following this news. A strong positive reaction aligns with Phathom’s broader push to expand VOQUEZNA’s GI footprint. The DDW 2026 presence, including a VOQUEZNA product theater and multiple posters, reinforces the commercialization story highlighted in recent earnings on Feb 26 and Apr 30. With shares still below the 18.31 52‑week high and an effective S-3ASR shelf in place, investors would need to watch for any future financing activity alongside sustained prescription growth.

Key Figures

DDW 2026 dates: May 2–5, 2026 Product theater time: 12:00 PM CDT Booth number: 2511 +5 more

8 metrics

DDW 2026 dates May 2–5, 2026 Digestive Disease Week annual meeting timing

Product theater time 12:00 PM CDT VOQUEZNA presentation on May 4, 2026 at DDW

Booth number 2511 VOQUEZNA exhibit booth at DDW 2026

Gastritis rate 3% Most common adverse reaction in erosive GERD healing indication

Diarrhea rate 2% Adverse reaction frequency in erosive GERD healing indication

Gastritis (maintenance) 6% Most common adverse reaction in maintenance of healed erosive GERD

eGFR threshold < 30 mL/min Severe renal impairment requiring VOQUEZNA dose reduction or avoidance

Pregnancy registry phone 1-866-609-1612 Contact for VOQUEZNA pregnancy exposure registry

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Q1 2026 earnings	Positive	-4.9%	Strong Q1 VOQUEZNA revenue growth and maintained 2026 guidance but shares fell.
Apr 20	Earnings call date	Neutral	+2.1%	Announcement of upcoming Q1 2026 results webcast and business update.
Apr 06	Investor conferences	Neutral	-0.8%	Planned participation in Raymond James and Needham investor conferences.
Mar 04	Sector market report	Neutral	-2.9%	DelveInsight report on H. pylori market growth and emerging therapies.
Feb 26	FY 2025 earnings	Positive	+10.1%	Strong 2025 revenue growth, financing steps, and 2026 profitability guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows generally constructive fundamentals and guidance, but price reactions have been mixed, including a selloff on the latest strong revenue growth report.

Recent Company History

Over the last few months, Phathom has focused on VOQUEZNA-driven growth and capital markets positioning. Earnings on Feb 26 and Apr 30 highlighted rapid revenue expansion with continued losses but reiterated 2026 profitability targets. Conference participation on Apr 6 and today’s DDW presence underscore active commercial and investor engagement. A broader H. pylori market report on Mar 4 provided thematic context but not company-specific data. Together, these events frame today’s DDW activity as part of an ongoing commercialization push.

Key Terms

potassium-competitive acid blocker, gastroesophageal reflux disease, helicobacter pylori, clostridioides difficile-associated diarrhea, +4 more

8 terms

potassium-competitive acid blocker medical

"VOQUEZNA® (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB)"

A potassium-competitive acid blocker is a type of medication that reduces stomach acid by blocking the cellular “pump” that produces acid, using a chemical that competes with potassium to stop the pump from working. For investors, it matters because this drug class can offer faster, longer-lasting acid control than older therapies, affecting market demand, pricing power, regulatory scrutiny, and commercial potential in conditions like ulcers and reflux.

gastroesophageal reflux disease medical

"approved for Gastroesophageal Reflux Disease (GERD)"

A chronic condition in which stomach acid frequently flows back into the tube connecting the mouth and stomach, causing repeated heartburn, irritation, and sometimes tissue damage; think of it as a one-way valve that no longer closes properly and lets corrosive material creep backward. It matters to investors because its prevalence and need for long-term medications, procedures, or devices drive steady demand, affect healthcare costs, and influence revenue and regulatory risk for drugmakers, device companies, insurers, and hospitals.

helicobacter pylori medical

"for the treatment of Helicobacter pylori (H. pylori) infection"

Helicobacter pylori is a curved bacterium that lives in the stomach and can cause long‑lasting inflammation, peptic ulcers and higher risk of stomach cancer. For investors it matters because the bacterium’s widespread infection drives demand for tests, treatments, antibiotics and potential vaccines, affecting clinical trial activity, regulatory approvals and sales—like a persistent leak that creates ongoing repair costs and market opportunities.

clostridioides difficile-associated diarrhea medical

"may be associated with an increased risk of Clostridioides difficile-associated diarrhea (CDAD)"

A gut infection caused by the bacterium Clostridioides difficile that leads to severe, sometimes recurring diarrhea and can require hospitalization. Think of it as a persistent plumbing problem in the digestive system that is hard to fix and often returns; for investors it matters because it drives demand for treatments, increases healthcare costs and hospital stays, and can affect pharmaceutical, biotech and hospital revenues as well as regulatory and reimbursement risks.

stevens-johnson syndrome medical

"Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis"

A rare but serious medical condition where the skin and mucous membranes blister and peel away, similar to a severe burn that affects large areas of the body and often requires hospital care. For investors it matters because it is a known, sometimes drug-triggered safety issue that can halt clinical trials, prompt regulatory warnings or recalls, and lead to large legal and financial consequences for companies producing implicated medicines or devices.

toxic epidermal necrolysis medical

"including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported"

A life‑threatening, rare reaction in which large areas of the skin and inner linings (like the mouth and eyes) slough off and die, often triggered by certain medications or infections; it resembles having a severe burn over much of the body. For investors, it matters because a confirmed case linked to a drug can halt clinical trials, prompt regulatory warnings or withdrawals, cause expensive legal claims, and materially damage a company’s sales and valuation.

acute tubulointerstitial nephritis medical

"Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA"

An inflammation of the tiny tubes and surrounding tissue in the kidney that help filter and clean the blood; when these structures swell or become irritated they can’t pass fluid and waste efficiently, similar to household pipes with blocked insulation. It matters to investors because the condition can cause sudden kidney dysfunction, trigger safety warnings, halt clinical trials or product sales, and lead to regulatory action, increased costs, or legal exposure for affected drugmakers.

chromogranin a medical

"Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity"

Chromogranin A is a protein released into the bloodstream by hormone-producing (neuroendocrine) cells and is commonly measured as a medical marker of neuroendocrine activity, including certain tumors. For investors, it matters because diagnostic tests and drugs that rely on or affect chromogranin A can drive demand, revenue and regulatory attention—think of it like a smoke detector: rising levels can signal a problem and shape the market for related medical products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/01/2026 - 08:00 AM

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week^® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois.

Phathom will engage with the medical and scientific community through a series of activities, including a product theater presentation on VOQUEZNA^® (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) approved for Gastroesophageal Reflux Disease (GERD), on Monday, May 4 at 12:00 PM CDT, along with a presence on the exhibit floor at booth number 2511.

The company will also present clinical and real-world data further characterizing the use of VOQUEZNA across three poster presentations.

“We look forward to engaging with the GI community at DDW and building on the progress we have made with VOQUEZNA. The data we are presenting this year spans clinical research, patient-reported outcomes, and real-world evidence, reflecting our continued commitment to advancing the treatment of patients with GERD,” said Steve Basta, President and Chief Executive Officer of Phathom. “DDW provides an important platform to share these insights, connect with experts, and continue strengthening our position in GI.”

Following the conclusion of DDW, poster abstracts will be available on Phathom’s publications and scientific section of the company website at www.phathompharma.com/publications/.

About VOQUEZNA
INDICATIONS AND USAGE
VOQUEZNA^® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults:

for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD.
to maintain healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD.
for the relief of heartburn associated with Non-Erosive GERD.
in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection.
in combination with amoxicillin for the treatment of H. pylori infection.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products.

For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with VOQUEZNA, refer to the Contraindications section of the corresponding prescribing information.

WARNINGS AND PRECAUTIONS

Presence of Gastric Malignancy: In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an early symptomatic relapse after completing treatment with VOQUEZNA. In older patients, also consider endoscopy.

Acute Tubulointerstitial Nephritis: Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and evaluate patients with suspected acute TIN.

Clostridioides difficile-Associated Diarrhea: Published observational studies suggest that proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridioides difficile-associated diarrhea (CDAD), especially in hospitalized patients. VOQUEZNA may also increase the risk of CDAD. Consider CDAD in patients with diarrhea that does not improve. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

CDAD has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with VOQUEZNA, refer to Warnings and Precautions section of the corresponding prescribing information.

Bone Fracture: Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, especially in patients receiving high dose (multiple daily doses) and long-term therapy (a year or longer). Bone fracture, including osteoporosis-related fracture, has also been reported with vonoprazan. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines.

Severe Cutaneous Adverse Reactions (SCAR): Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA at the first signs or symptoms of SCAR or other signs of hypersensitivity and consider further evaluation.

Vitamin B12 (Cobalamin) Deficiency: Long-term use of acid-suppressing drugs can lead to malabsorption of Vitamin B12 caused by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If clinical symptoms consistent with vitamin B12 deficiency are observed in patients treated with VOQUEZNA, consider further workup.

Hypomagnesemia and Mineral Metabolism: Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.

Consider monitoring magnesium levels prior to initiation of VOQUEZNA and periodically in patients expected to be on prolonged treatment, in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia or drugs that may cause hypomagnesemia. Treatment of hypomagnesemia may require magnesium replacement and discontinuation of VOQUEZNA.

Consider monitoring magnesium and calcium levels prior to initiation of VOQUEZNA and periodically while on treatment in patients with a preexisting risk of hypocalcemia. Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing VOQUEZNA.

Interactions with Diagnostic Investigations for Neuroendocrine Tumors: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily discontinue VOQUEZNA treatment at least 4 weeks before assessing CgA levels and consider repeating the test if initial CgA levels are high.

Fundic Gland Polyps: Use of VOQUEZNA is associated with a risk of fundic gland polyps that increases with long-term use, especially beyond one year. Fundic gland polyps have been reported with vonoprazan in clinical trials and during postmarketing use with PPIs. Most patients who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

ADVERSE REACTIONS:

Healing of Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include gastritis (3%), diarrhea (2%), abdominal distention (2%), abdominal pain (2%), and nausea (2%).

Maintenance of Healed Erosive GERD: The most common adverse reactions (≥3% of patients in the VOQUEZNA arm) include gastritis (6%), abdominal pain (4%), dyspepsia (4%), hypertension (3%), and urinary tract infection (3%).

Relief of Heartburn Associated with Non-Erosive GERD: The most common adverse reactions (≥2% of patients in the VOQUEZNA arm) include abdominal pain (2%), constipation (2%), diarrhea (2%), nausea (2%), and urinary tract infection (2%).

Treatment of H. Pylori Infection (VOQUEZNA and Amoxicillin): The most common adverse reactions (≥2% in any treatment arm) include diarrhea (5%), abdominal pain (3%), vulvovaginal candidiasis (2%), nasopharyngitis (2%), dysgeusia (1%), headache (1%), and hypertension (1%).

Treatment of H. Pylori Infection (VOQUEZNA, Amoxicillin and Clarithromycin): The most common adverse reactions (≥2% in any treatment arm) include dysgeusia (5%), diarrhea (4%), vulvovaginal candidiasis (3%), headache (3%), abdominal pain (2%), hypertension (2%), and nasopharyngitis (<1%).

For more information on adverse reactions and laboratory changes with amoxicillin or clarithromycin, refer to Adverse Reactions section of the corresponding prescribing information.

DRUG INTERACTIONS
VOQUEZNA has the potential for clinically important drug interactions, including interactions with drugs dependent on gastric pH for absorption, drugs that are substrates for certain CYP enzymes, and some diagnostic tests. Avoid concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Information for more details about important drug interactions. Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan.

For information about drug interactions, contraindications, and warnings and precautions of antibacterial agents (amoxicillin or clarithromycin) indicated in combination with VOQUEZNA, refer to their corresponding prescribing information.

USE IN SPECIFIC POPULATIONS

Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VOQUEZNA during pregnancy. Healthcare providers are encouraged to register patients by calling 1-866-609-1612 or visiting https://voqueznapregnancyregistry.com/.

Lactation: There are no data on the effects of vonoprazan on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VOQUEZNA and any potential adverse effects on the breastfed child from VOQUEZNA or from the underlying maternal condition.

Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR < 30 mL/min). Use of VOQUEZNA is not recommended for the treatment of H. pylori infection in patients with severe renal impairment.

Hepatic Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with moderate to severe hepatic impairment (Child-Pugh Class B and C). Use of VOQUEZNA is not recommended for the treatment of H. pylori infection in patients with moderate to severe hepatic impairment.

You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here to see full Prescribing Information for VOQUEZNA.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

5/26 US-VPZ-26-0125

FAQ

When will Phathom Pharmaceuticals (PHAT) present VOQUEZNA at DDW 2026?

Phathom will present VOQUEZNA in a product theater on May 4, 2026 at 12:00 PM CDT. According to Phathom, the company will also display posters and exhibit at booth 2511 during DDW May 2–5 in Chicago.

Where can investors find Phathom (PHAT) DDW 2026 abstracts and posters?

Posters and abstracts will be available on Phathom's publications page at www.phathompharma.com/publications/ after DDW. According to Phathom, the materials will be posted following the conference's conclusion for public access.

Does the DDW 2026 presentation affect VOQUEZNA's approved uses for patients?